Table 2.
GRADE table for health outcomes, aspirin vs. control
| Certainty assessment | No. of patients | Effect of aspirin vs. control | Confidence in efficacy statement | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other | Aspirin | Avoid aspirin | Relative (95% CI) | Absolute (95% CI) | Efficacy statement | |
| Deaths (follow-up: mean 24 months) | ||||||||||||
| 1 | Randomised trials | Seriousa | Not serious | Seriousb | Very seriousc | None | 26/150 (17.3% mortality) | 24/147 (16.3% mortality) | OR 1.07 (0.58 to 1.97) | 9 more deaths per 1000 (from 62 fewer to 114 more) | Aspirin has no significant effect on deaths |
⨁◯◯◯ Very low |
| Entry into care home (follow up: mean 36 months) | ||||||||||||
| 1 | Randomised trials | Seriousa | Not serious | Seriousb | Very seriousc | None | 156 | 154 | HR 0.94 (0.67 to 1.31) | 22 fewer entry per 1000 (from 132 fewer to 98 more) | Aspirin has no significant effect on entry into care home |
⨁◯◯◯ Very low |
| 52.0% care home entry | ||||||||||||
CI, confidence interval; OR, odds ratio; HR, hazard Ratio; MD, mean difference
aCochrane risk of bias tool highlighted risk from deviation from intended treatment (includes lack of blinding) and missingness
bIncludes only those with Alzheimer’s disease and without high vascular risk
cConfidence interval crosses lines of clinical importance on both benefit and harm